A Phase 1 clinical trial involving insulin NNC0471-0119 H, related to insulin aspart, was marked completed as of September 10, 2026. The study, registered as NCT06809621, was titled "A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump."
The trial's status is listed as COMPLETED in the registry. It was designed to examine how this insulin formulation behaves in the body when administered through an insulin pump in participants with type 1 diabetes.
No results, efficacy data, or safety findings have been provided alongside this status update. The completion designation reflects only that the study has concluded according to its registered record, not any specific outcome or conclusion drawn from the data collected.
Insulin aspart remains an approved compound. This particular Phase 1 study represents an investigation into a related insulin molecule's pharmacokinetic or pharmacodynamic profile using pump-based delivery. Further details, including any posted results, would typically follow through the official clinical trial registry listing.
Readers interested in background on insulin aspart can consult the compound overview for additional context on its approved uses and development history.